Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
New website launched to help prevent spread of hepatitis C

A group of researchers launched a new website Wednesday that lays out a roadmap to curb the spread of hepatitis C. HepVu is the result of a public-private partnership aimed to help the estimated 3.9 million Americans who currently have or have had hepatitis C

Published
28 April 2017
From
ModernHealthcare.com
New Canadian guideline: No screening for hepatitis C in adults not at increased risk

The Canadian Task Force on Preventive Health Care recommends against screening for chronic hepatitis C virus in adults at low risk in a guideline published in Canadian Medical Association Journal.

Published
25 April 2017
From
Eurekalert Inf Dis
New hepatitis data highlight need for urgent global response

New WHO data reveal that an estimated 325 million people worldwide are living with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. The WHO Global hepatitis report, 2017 indicates that the large majority of these people lack access to life-saving testing and treatment. As a result, millions of people are at risk of a slow progression to chronic liver disease, cancer, and death.

Published
21 April 2017
From
World Health Organization
The Medicines Patent Pool and Pharco Pharmaceuticals Sign Licence for Promising Hepatitis C Drug Candidate Ravidasvir

The Medicines Patent Pool (MPP) announced a new licence and technology transfer agreement with Egyptian company Pharco Pharmaceuticals for ravidasvir (RAV), an investigational direct-acting antiviral (DAA) with the potential of working across all six major hepatitis C genotypes. The agreement, signed on the sidelines of the International Liver Congress in Amsterdam, will enable competitive supply of RAV in low- and middle-income countries (LMICs) including high prevalence nations Russia, Ukraine, Egypt and Iran.

Published
21 April 2017
From
Medicines Patent Pool
Long-term antibiotic prophylaxis reduces mortality in people with advanced liver disease

A multicenter, randomized, controlled study presented today found that long-term oral antibiotic therapy with norfloxacin improved the prognosis of people with life-threatening advanced liver disease. The study, presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, showed that norfloxacin administration for six months was associated with a reduced risk of death and infection at six months in patients with Child-Pugh class C cirrhosis, a very severe and advanced stage of liver disease.

Published
20 April 2017
From
EASL press release
Top 10 Pharmaceutical Companies 2017

The global pharmaceutical market was estimated in USD 1.1 trillion in 2016. The top ten pharmaceutical companies in this market had share of around 40% in 2016 and the top 15 approximately 50%. A comparative analysis of the top 15 organisations was used to develop a ranking for these companies. The analysis shows that by far the biggest earners in terms of classes of drugs were oncology drugs and related immune-modulators. Two of the top ten companies featured hepatitis C drugs in their largest earners and one (Gilead) HIV drugs. The HPV vaccine Gardasil also made a lot of money for its developers Merck.

Published
18 April 2017
From
LinkedIn
Hepatitis drug patent application opposed

A health advocacy group voiced its opposition Tuesday to a patent application for hepatitis C medicine, Sofosbuvir, filed with the Department of Intellectual Property's Patent Office, which the group said was unjustified. If approved, the drug patent would bar fair competition by precluding the development and distribution of generic versions of Sofosbuvir at lower prices, said a group of 30 activists led by the Aids Access Foundation and Thai Network of People Living with HIV/Aids.

Published
12 April 2017
From
Bangkok Post
WHO prequalifies first generic active ingredient for hepatitis C medicines

On 31 March 2017, WHO for the first time prequalified a generic active pharmaceutical ingredient (API) for hepatitis C – sofosbuvir. Sofosbuvir is an essential ingredient for new, highly effective medicines to treat hepatitis C called direct active antivirals (DAAs). The prequalified product’s manufacturer is Mylan Laboratories Ltd - India.

Published
05 April 2017
From
World Health Organization
Scale up of hepatitis C treatment possible as Brazil rejects patent on key drug

Treatment for hepatitis C using the key drug sofosbuvir could be vastly scaled up in Brazil after the decision by the National Agency of Health Surveillance (Anvisa) to reject a key patent application on the drug marketed by pharmaceutical corporation Gilead. The decision could pave the way to enable generic competition in Brazil, which should lead to price reductions, making it more affordable to scale up treatment.

Published
03 April 2017
From
MSF
France Reaches Agreement With Gilead To Drop Prices Of Hepatitis C Treatment

New prices are expected to come into effect on 1 April. For Sovaldi, it will drop from €41,000 euros to less than €28,700 euros for the treatment of hepatitis C.

Published
03 April 2017
From
Intellectual Property Watch
← First12345...125Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.